News Column

CORONADO BIOSCIENCES INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations.

May 12, 2014

References in this report to "we," "us," "our," "the Company" and "Coronado" refer to Coronado Biosciences, Inc. and its subsidiaries.

Forward-Looking Statements

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included elsewhere in this Form 10-Q. Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"), including, without limitation, statements regarding our expectations, beliefs, intentions or future strategies that are signified by the words "expect," "anticipate," "intend," "believe," "may," or similar language. All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Our business and financial performance are subject to substantial risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. In evaluating our business, you should carefully consider the information set forth under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2013.


Since inception, we have been a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, namely CNDO-201 or Trichuris suis ova ("TSO") and CNDO-109, as more fully described below. As part of our growth strategy, we plan to identify, evaluate and potentially in-license, acquire or invest in pharmaceutical and biotechnology products, technologies and/or companies. We may also, from time to time, consider financing existing or later-acquired products, technologies or companies through partnerships, joint ventures, direct financings, and/or public or private spin-outs. We believe these activities will diversify our product development and, over time, may enhance shareholder value through potential royalty, milestone and equity payments, fees as well as potential product revenues.

Our two principal pharmaceutical product candidates currently in clinical development are:

• TSO, or CNDO-201, the microscopic eggs of the porcine whipworm, for the

treatment of autoimmune diseases, such as Crohn's disease, or CD, ulcerative

colitis, or UC, multiple sclerosis, or MS, autism, psoriasis, and type 1

diabetes, or T1D; and

• CNDO-109, a biologic that activates natural killer, or NK, cells of the immune

system to seek and destroy cancer cells, for the treatment of acute myeloid


In October 2013, we announced that our TRUST-I study did not meet its primary endpoint of improving response which was driven by a higher-than-expected placebo response rate in patients with CDAI<290. While we are continuing to analyze the trial data, the results of this trial negatively impact the potential for successful development of TSO.

In November 2013, Dr. Falk Pharma GmbH ("Falk"), our development partner, informed us that an independent data monitoring committee had conducted a second interim analysis of data from its Phase 2 clinical for CD known as TRUST-II and recommended that the trial be stopped due to lack of efficacy and noted no safety concerns. Falk adopted the committee's recommendations and discontinued the study.

We are continuing to evaluate the data from TRUST-I. We will use this analysis, along with the clinical study report of TRUST-II data, other current data on TSO and other factors to determine our future development plans for TSO. Our current focus is on our investigator initiated studies in psoriasis and autism.

In March 2014, we submitted an Investigational New Drug Study to the U.S. Food and Drug Administration for the treatment of autism in 20 pediatric patients. We expect the study to commence in mid-2014.

In February 2014, we repaid in full our term loan with Hercules Technology Growth Capital, Inc. (the "Hercules Note") and entered into a new promissory note ("IDB Note") with Israel Discount Bank of New York ("IDB"), under which we can borrow up to $15.0 million. At March 31, 2014, the amount of debt outstanding under the IDB Note was $14.0 million. (See Note 4 of Notes to Unaudited Condensed Consolidated Financial Statements).

In March 2014, we made the decision to abandon our plans to build-out the Woburn, MA manufacturing facility and to close our New York, NY office. As a result, we commenced marketing both facilities for sub-lease. In April 2014, we entered into a sub-lease arrangement for our New York, NY office for the remaining term of the lease. During the three month period ended March 31, 2014, a lease impairment and fixed asset impairment charge related to these facilities of $0.8 million was recorded in our Condensed Consolidated Statements of Operations. (See Note 6 of Notes to Unaudited Condensed Consolidated Financial Statements).


In March 2014, we terminated our Sponsored Research Agreement with Freie UniversitÄt Berlin effective June 30, 2014 and recorded a charge of $0.2 million related to the contract termination in our Unaudited Condensed Consolidated Statements of Operations. (See Note 7 of Notes to Unaudited Condensed Consolidated Financial Statements).

On March 17, 2014, we made a $250,000 investment in Argus Neurooptics LLC ("Argus"), a medical device company developing a laser device to treat migraine headaches. The investment represents a 35% ownership position in Argus. The Company elected the fair value option to record this investment. (See Note 8 of Notes to Unaudited Condensed Consolidated Financial Statements).

Also on March 17, 2014, we provided a $50,000 bridge loan to Nuro Pharma, Inc. ("Nuro"). Nuro is an emerging specialty pharmaceutical company developing, marketing and distributing Epilepsy drugs. The bridge loan is payable in 90 days, accrues interest at a rate of 8% and is secured by Nuro's assets. The Company recorded this bridge loan in prepaid and other current assets in its Unaudited Condensed Consolidated Balance Sheets as of March 31, 2014.

Results of Operations General

To date, we have not generated any revenues from operations and, at March 31, 2014, we had an accumulated deficit of $128.7 million, primarily as a result of research and development expenses, purchase of in-process research and development and general and administrative expenses. While we may in the future generate revenue from a variety of sources, including license fees, milestone payments, research and development payments in connection with strategic partnerships and/or product sales, our product candidates are at an early stage of development and may never be successfully developed or commercialized. Accordingly, we expect to continue to incur substantial losses from operations for the foreseeable future and there can be no assurance that we will ever generate significant or any revenues.

Research and Development Expenses

Conducting research and development is central to our business and aggregated expenses of $72.2 million for the period from inception (June 28, 2006) to March 31, 2014. Noncash, stock-based compensation expense included in research and development for the three months ended March 31, 2014 and 2013, was $0.3 million and $0.8 million, respectively, and $8.0 million from inception to March 31, 2014. Research and development expenses consist primarily of:

• employee-related expenses, which include salaries and benefits, and rent


• noncash stock-based compensation expense;

• license fees and milestone payments related to in-licensed products and

intellectual property;

• expenses incurred under agreements with CROs, investigative sites and

consultants that conduct or provide other services relating to our clinical trials and our preclinical activities;

• the cost of acquiring clinical trial materials from third-party manufacturers;


• costs associated with non-clinical activities, patent filings and regulatory


We expect to continue to incur expenses related to our research and development activities for the foreseeable future as we develop our existing product candidates and new product candidates. Since product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials, we expect that our research and development expenses may increase in the future. In addition, if our product development efforts are successful, we expect to incur substantial costs to prepare for potential commercialization of any late-stage product candidates and, in the event one or more of these product candidates receive regulatory approval, to fund the launch of the product.

From inception through March 31, 2014, direct, external development costs incurred for our TSO product development program were $27.3 million, excluding $21.7 million of in-process research and development costs related to our acquisition of the asset in 2011 and its manufacturing rights in 2012. From inception through March 31, 2014, direct, external development costs incurred for our CNDO-109 product development program were $8.9 million.


General and Administrative Expenses

General and administrative expenses consist principally of personnel-related costs, professional fees for legal, consulting, audit and tax services, rent and other general operating expenses not otherwise included in research and development and such expenses were $28.5 million from inception through March 31, 2014. Noncash, stock-based compensation expense included in general and administrative expenses for the three months ended March 31, 2014 and 2013, was $0.8 million and $0.7 million, respectively, and $6.5 million from inception through March 31, 2014. We anticipate general and administrative expenses will increase in future periods, reflecting continued and increasing costs associated with:

• support of our expanded research and development activities; and

• an expanding infrastructure and increased professional fees and other costs

associated with the regulatory requirements and increased compliance associated with being a public reporting company.

Comparison of three months ended March 31, 2014 and 2013

For the three months ended March 31, Change ($ in thousands) 2014 2013 $ % Operating expenses: Research and development $ 4,487$ 5,974$ (1,487 ) (25 )% General and administrative 2,095 2,484 (389 ) (16 )% Loss from operations (6,582 ) (8,458 ) 1,876 (22 )% Interest income 178 76 102 134 % Interest expense (966 ) (476 ) (490 ) 103 % Net loss $ (7,370 )$ (8,858 )$ 1,488 (17 )%

Research and development expenses decreased $1.5 million, or 25%, from the three months ended March 31, 2013 to the three months ended March 31, 2014. This decrease was primarily due to a reduction in TSO product development costs related to the wind down of Phase 2 of the TRUST-I trial. Stock-based compensation expense also decreased $0.5 million primarily due to a reduction in the mark-to-market value of our non-employee option grants. These decreases in expense were partially offset by a $0.7 million charge related to the decision to delay manufacturing of TSO in the Woburn, MA facility. We expect to incur expenses related to our research and development efforts going forward with existing products as well as related to new products.

General and administrative expenses decreased $0.4 million, or 16%, from the three months ended March 31, 2013 to the three months ended March 31, 2014, due to a $0.4 million decrease in personnel costs primarily resulting from the November 2013 termination of certain personnel in connection with the Company's effort to lower operating expenses and realign the organization to work more efficiently and a $0.1 million decrease in consulting costs. This decrease was partially offset by stock-based compensation expense, which increased $0.1 million due to restricted stock grants made to our Executive Vice Chairman, Strategic Development and the independent members of our board of directors in the three months ended March 31, 2014.

Interest expense in 2014 primarily relates to interest on the Hercules Note, which included a prepayment penalty of $0.3 million, representing 2% of the outstanding debt. The increase in interest income in 2014 compared to the same period last year was primarily due to higher cash balances.


Liquidity and Capital Resources

To date, we have funded our operations through the sale of debt and equity securities, aggregating $167.4 million of net proceeds. At March 31, 2014, we had cash and cash equivalents of $80.0 million and restricted cash of $14.0 million securing the IDB Note.

In February 2014, we paid off the Hercules Note and entered into the IDB Note. Early payment of the Hercules Note approximated $14.0 million consisting of principal of $13.2 million, end of term charge of $0.4 million, a prepayment fee of $0.1 million and interest of $0.3 million. Prior to repayment, in January 2014, the Company made a scheduled principal payment of $0.5 million on the Hercules Note.

We may require additional financing to fully develop, and prepare regulatory filings and obtain regulatory approvals for our existing product candidates (and potentially new product candidates), fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for our potential products (and potentially new product candidates), sales and marketing capabilities. We have funded our operations to date primarily through the sale of equity and debt securities. We believe that our current cash is sufficient to fund operations for at least the next twelve months. Our failure to raise capital as and when needed would have a material adverse impact on our financial condition and our ability to pursue our business strategies. We may seek funds through equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding, particularly subsequent to the negative results from our TRUST-I clinical trial, may not be available to us on acceptable terms or at all. If adequate funds are not available to us when needed, we may be required to delay, curtail or eliminate one or more of our research and development programs and, potentially, delay our growth strategy.

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Edgar Glimpses

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters